<DOC>
	<DOCNO>NCT00006376</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness R115777 treat patient advanced bladder cancer .</brief_summary>
	<brief_title>R115777 Treating Patients With Advanced Bladder Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine efficacy R115777 term objective response patient advance transitional cell cancer urothelial tract . II . Determine safety treatment regimen patient . III . Determine time disease progression patient treatment regimen . OUTLINE : This multicenter study . Patients receive oral R115777 every 12 hour 21 day absence disease progression unacceptable toxicity . Treatment repeat every 28 day least 2 course . Patients follow every 3 month 5 year . PROJECTED ACCRUAL : A total 18-32 patient accrue study .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Ureteral Neoplasms</mesh_term>
	<mesh_term>Tipifarnib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm transitional cell carcinoma urothelial tract curable surgery radiotherapy Bladder , renal pelvis , ureter Stage II , III , IV ( T24 , N03 , M01 ) unresectable disease Poorly differentiate transitional cell carcinoma predominant transitional cell carcinoma foci squamous differentiation rare focus adenocarcinoma allow No adenocarcinoma , small cell carcinoma , sarcoma , squamous cell carcinoma Bidimensionally measurable disease No disease confine bladder No soft tissue disease irradiate within past 2 month No know active CNS disease PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count great 1,500/mm3 Platelet count great 100,000/mm3 Hepatic : SGOT great 2 time upper limit normal ( ULN ) Bilirubin normal Renal : Creatinine great 2 time ULN Other : No unresolved , active bacterial infection require antibiotic No prior malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer , carcinoma situ cervix , adequately treated stage I II cancer complete remission Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent myeloid colony stimulate factor Chemotherapy : At least 12 month since prior adjuvant neoadjuvant chemotherapy recover Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics At least 4 week since prior radiotherapy recover Surgery : At least 4 week since prior surgery recover Other : No prior systemic therapy ( include investigational agent ) metastatic bladder cancer At least 4 week since prior intravesical therapy recover At least 30 day since prior participation investigational drug trial No concurrent intravesical therapy No concurrent therapy cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2005</verification_date>
	<keyword>stage II bladder cancer</keyword>
	<keyword>stage III bladder cancer</keyword>
	<keyword>recurrent bladder cancer</keyword>
	<keyword>stage IV bladder cancer</keyword>
	<keyword>transitional cell carcinoma bladder</keyword>
	<keyword>metastatic transitional cell cancer renal pelvis ureter</keyword>
	<keyword>regional transitional cell cancer renal pelvis ureter</keyword>
	<keyword>recurrent transitional cell cancer renal pelvis ureter</keyword>
</DOC>